Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension
Gautam V Ramani, Myung H ParkUniversity of Maryland, Baltimore, MD, USAAbstract: Sildenafil is an orally administered phosphodiesterase type 5 inhibitor that is approved for the treatment of pulmonary arterial hypertension (PAH). The hemodynamic effects of sildenafil are mitigated primarily via pote...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/update-on-the-clinical-utility-of-sildenafil-in-the-treatment-of-pulmo-a4377 |